Tumor treating fields (TTFields) induce autophagy in glioma cells; Y Porat et al; Saturday, Nov. 19; abstract: #EXTH-30
Effects of tumor treating fields (TTFields) and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells; PA Clark et al; Saturday, Nov. 19; abstract: #EXTH-25
Ad Statistics
Times Displayed: 113072
Times Visited: 6738 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Tumor Treating Field (TTFields) effects on glioblastoma cells are augmented by mitotic checkpoint inhibition; AF Kessler et al; Saturday, Nov. 19; abstract: #EXTH-07
Cytostatic agents combined with tumor treating fields (TTFields) in glioma cell lines; M Groves et al; Saturday, Nov. 19; abstract: #NIMG-39
Tumor cells induce immune activation phenotype in immune cells following TTFields activation; T Holtzman et al; Friday, Nov. 18; abstract: #IMST-26
Evaluating the in-vitro effects of tumor treating fields on T cell responses; G Diamant et al; Friday, Nov. 18; abstract: #IMST-30
Clinical
METIS: A phase III study of radiosurgery with TTFields for 1-10 brain metastases; M Mehta et al; Saturday, Nov. 19; abstract: #BMET-03
One year with Optune® in routine use: first report on clinical experiences in Germany; M Misch et al; Friday, Nov. 18; abstract: #RARE-44
Analysis of glioblastoma physical characteristics in patients benefiting from tumor treating electric fields therapy; PP San et al; Friday, Nov. 18; abstract: #RTHP-19
Compliance and duration of treatment with tumor treating fields (TTFields) in adjuvant treatment for newly diagnosed glioblastomas (GBMs) improves progression-free survival (PFS) and overall survival (OS); SA Jeyapalan et al; Friday, Nov. 18; abstract: #RTHP-29
Pilot study of Optune (Novo-TTF-100A) for recurrent atypical and anaplastic meningioma; G Wu et al; Friday, Nov. 18; abstract: #ACTR-43
Classification of dermatologic adverse events and management strategies in patients receiving therapy with Optune for high grade gliomas; D Jennings et al; Friday, Nov. 18; abstract: #QLIF-11
The use of a programmable shunt in a patient, treated with Optune: feasibility report; L Schreiber et al; Friday, Nov. 18; abstract: #RARE-24
Survival benefit with triple chemotherapy and TTFields for glioblastoma; G Lu et al; Friday, Nov. 18; abstract: #PDCT-16
Patterns of glioblastoma recurrence in low field intensity regions during TTFields treatment; J Battiste et al; Saturday, Nov. 19; abstract: #NIMG-61
Patterns of compliance in the use of tumor treating fields (Optune) for brain tumors; M Pandey et al; Friday, Nov. 18; abstract: #ACTR-31
Use of tumor treating fields in brain metastases from ovarian cancer, a case report; M Pandey et al; Saturday, Nov. 19; abstract: #BMET-21
